Innovent Biologics, Inc. (HKG:1801)
Hong Kong · Delayed Price · Currency is HKD 80.75
+0.05 (0.06%)
At close: Dec 24, 2025
Innovent Biologics Employees
Innovent Biologics had 5,659 employees as of December 31, 2024. The number of employees increased by 787 or 16.15% compared to the previous year.
Employees
5,659
Change (1Y)
787
Growth (1Y)
16.15%
Revenue / Employee
2.02M HKD
Profits / Employee
200.45K HKD
Market Cap
138.95B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5,659 | 787 | 16.15% |
| Dec 31, 2023 | 4,872 | -422 | -7.97% |
| Dec 31, 2022 | 5,294 | -274 | -4.92% |
| Dec 31, 2021 | 5,568 | 2,289 | 69.81% |
| Dec 31, 2020 | 3,279 | 1,297 | 65.44% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 24,379 |
| CSPC Pharmaceutical Group | 21,400 |
| WuXi Biologics | 12,575 |
| BeOne Medicines AG | 11,000 |
| Hansoh Pharmaceutical Group Company | 8,989 |
| JD Health International | 3,564 |
| Akeso | 3,035 |
| WuXi XDC Cayman | 2,041 |
Innovent Biologics News
- 2 hours ago - China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval - PRNewsWire
- 13 days ago - Innovent's Mazdutide Shows Significant Weight Loss & Metabolic Benefits In Chinese Adolescents - Nasdaq
- 15 days ago - Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody - PRNewsWire
- 16 days ago - Innovent's PECONDLE Delivers Durable Efficacy And Safety In Phase 3 Psoriasis Trial - Nasdaq
- 16 days ago - ASH 2025 | Updated Data for Ascentage Pharma's Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment - Benzinga
- 16 days ago - Innovent Announces PECONDLE® (Picankibart Injection) Phase 3 Study (CLEAR-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis - PRNewsWire
- 17 days ago - ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma - PRNewsWire
- 20 days ago - Innovent, Takeda Close $11.4 Bln Collaboration To Advance Next-Generation IO And ADC Therapies - Nasdaq